2359.HK Earnings — WuXi AppTec Co., Ltd.
HKSE
Updated
When is 2359.HK's next earnings date?
WuXi AppTec Co., Ltd. (2359.HK) has not announced its next earnings date yet. Its most recent earnings report was on Monday, October 26, 2026.
How did 2359.HK do in its last earnings report?
In its most recent report on Oct 26, 2026, WuXi AppTec Co., Ltd. posted EPS of $3.34 versus the $3.43 estimate, a miss of 2.6%. Revenue was $18.47B against a $18.76B estimate.
How much does 2359.HK stock move after earnings?
2359.HK beat EPS estimates in 1 of its last 2 reported quarters.
About WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
🤖 AI Earnings Analysis
Results are weak: EPS of $3.34 missed estimates by $0.09, while revenue of $18.5 billion fell short by $0.3 billion. With no reported catalyst or sector context, growth momentum remains unclear.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-26 | 3.43 | 3.34 | -2.62% | $18.47B | ❌ Miss | — | — | — | |
| 2026-08-03 | 1.82 | 2.53 | — | $19.12B | ✅ Beat | — | — | — |
Showing last 2 quarters.